GlassScriptPhysician profile
Michelle Berry
NPI 1033194527
$10,229.34
in general payments reported to CMS, 2019-2025
51 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $1,392 · 2021: $2,181 · 2022: $1,234 · 2023: $974 · 2024: $1,581 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,443.23 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.94 | 2020-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $995.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $948.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $868.19 | 2019-2025 | |
| Amarin Pharma, INC. | $593.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $528.34 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $471.03 | 2019-2024 | Xarelto |
| Amgen INC. | $389.92 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $359.19 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $351.89 | 2019-2024 | Trintellix |
| Eisai INC. | $335.10 | 2020-2021 | |
| Axsome Therapeutics, INC. | $310.95 | 2024-2025 | Auvelity, Symbravo, Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $308.10 | 2024-2025 | |
| Exact Sciences Corporation | $235.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $231.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.